Navigation Links
Marken Opens Two Pharmaceutical Depots In New York & Germany
Date:8/30/2012

RESEARCH TRIANGLE PARK, N.C., Aug. 30, 2012 /PRNewswire/ -- Marken announced today the completion of the first phase of its plan to create a global pharmaceutical depot network that will allow it to satisfy its clients' needs for global distribution. Two new depots have been completed:  one in Frankfurt, Germany and one in Farmingdale, New York. The launch of these two central depots, when added to the existing operational depots in Singapore, Mexico and Argentina and further supplemented by its own 3rd party depot network, now completes Phase I of the global Marken depot network plan. This network has been built based on an extensive analysis of client needs as well as geographical needs, allowing large Phase III clinical trials to be conducted in a cost efficient and optimized manner.

(Logo: http://photos.prnewswire.com/prnh/20110930/NY78064LOGO )

"Today marks an important milestone for Marken.  Having these two new central depots allows us to serve our clients with global distribution services and, more importantly, to serve our clients who seek comprehensive and efficient global distribution.  Phase One is complete.  We are now pushing forward with Phase Two, which will include more depots in key countries around the world such as China, Brazil and Russia," said Gerit Offenhauser, Senior Vice President, Clinical Trials Distribution for Marken.

Marken's depots provide secure temperature controlled storage and distribution for drugs, medical devices and diagnostic equipment.  They are located near existing branch operations in order to take advantage of well established customer service, operations import /export and administrative support. Each of Marken's depots are connected through the Solo platform, a state-of-the-art, 21 CFR part 11 validated, cloud based inventory management system which can interface with IRT for improved inventory reconciliation.  This interface allows our client to track dosages at the patient level.

Wes Wheeler, Chief Executive Officer of Marken, said, "We are proud to expand our pharmaceutical service depot network to Frankfurt and New York. Having a presence in these cities ensures that Marken continues to serve our clients with full service, global clinical supply chain solutions.  Marken will continue to invest in facilities and technologies which will provide the highest quality courier and logistics services."

About Marken

Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment in naive geographies.

www.marken.com


'/>"/>
SOURCE Marken
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Marken Launches Exclusive Shipping System for Specimen Logistics
2. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
3. CoreLab Partners Opens Office in Tokyo, Japan
4. Alchem International Opens Sales and Marketing Office in the U.S.
5. Stevenage Bioscience Catalyst Opens With Exciting Year Ahead
6. PRA Opens Office in Singapore
7. Discovery opens door to low-cost negative refraction, new products and industries
8. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
9. Data mining opens the door to predictive neuroscience
10. Scotland opens stem cell research center and bio-medical incubator
11. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... media products engineered to radically streamline culture processes, minimize processing time, significantly ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. ... biopharmaceutical company focused on developing and commercializing products ... unmet medical need, announced today the long-term follow-up ... SGX942 (dusquetide), a first-in-class Innate Defense Regulator (IDR), ... head and neck cancer patients undergoing chemoradiation therapy ...
(Date:12/8/2016)... 2016 Savannah River Remediation LLC group ... NewTechBio,s NT-MAX Lake & Pond Sludge and ... in conjunction with Hexa Armor/ Rhombo cover manufactured ... Pollutant Discharge Elimination System requirements. The ... history of elevated pH levels, above 8.5, especially ...
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selectorâ„¢ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016 Valencell , the leading innovator ... seen a third consecutive year of triple digit growth ... 2016 with a 360 percent increase in companies who ... was driven by sales of its wrist and ear ... its technology for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... Texas , Dec. 1, 2016   ... today announced BioLock , an electrocardiogram (ECG) ... health monitoring, a key IoT asset. The smart ... into a vehicle,s steering wheel and mobile devices ... simple touch. As vehicle technology advances, ...
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
Breaking Biology News(10 mins):